CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage
Status:
Not yet recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
1) To examine the impact of Circulating tumor DNA (ctDNA) (expressed as mean tumor molecules
per ml) on treatment decision making in patients with early stage breast cancer after
neoadjuvant therapy and surgery
Secondary Objectives:
1. Understand ctNDA kinetics in the neoadjuvant and adjuvant setting
2. To identify any associations between clinical staging and measurable ctDNA